

# MS in the COVID era

---

**Dr Céline Louapre**

Sorbonne University, Pitié Salpêtrière Hospital  
and Paris Brain Institute, Paris, France

[celine.louapre@aphp.fr](mailto:celine.louapre@aphp.fr)

Twitter: @clouapre



# Disclosures

---

- Speaker or consulting fees, none related to the teaching course  
→ Biogen, Merck, Roche, Novartis, Teva, Sanofi
- Research grant, none related to the teaching course  
→ Biogen

# Learning objectives: MS in the COVID era


---

**During this teaching course, we will address the following questions:**

1. What are the key messages from the MS and COVID registries?
2. How did clinical management of patients with MS change in terms of treatment decision?
3. What do we know about immune response to SARS-CoV-2 in patients with MS?
4. Is there a specific SARS-CoV-2 vaccination strategy in patients with MS?

# Key messages: MS in the COVID era

---



## Identified risk factors for severe COVID-19

- Neurological disability
- Age
- Cardiac comorbidity
- Anti-CD20
- Corticosteroids



## MS treatments

- Risk/benefit ratio of MS treatments must be assessed individually based on MS activity, disease course and comorbidities, but overall, initiating treatment should not be delayed



## Immune response to SARS-CoV-2

- Anti-CD20 reduce humoral response to SARS-CoV-2 after COVID-19, but data on cellular immune response are warranted



## Patients with MS should receive SARS-CoV-2 vaccination

- at any time for patients without treatment
- before treatment initiation
- during treatment, although immune response might be decreased on specific immunosuppressants

# Bibliography: MS in the COVID era

---

1. Louapre C, et al. *JAMA Neurol.* 2020;77:1079–88;
2. Zabalza A, et al. *Eur J Neurol.* 2021; <https://doi.org/10.1111/ene.14690>;
3. Sormani MP, et al. *Ann Neurol.* 2021;89:78
4. Salter A, et al. *JAMA Neurol.* 2021;78(6):699-708
5. Sahraian, Mohammad Ali, et al. *Multiple sclerosis and related disorders.* 2020 Nov;46:102472
6. Van Kempen ZLE, et al. *JAMA Neurol.* 2021 Jul 1;78(7):880-882
7. Sormani MP, et al. *Ann Clin Transl Neurol.* 2021 Jul 7. <https://doi.org/10.1002/acn3.51408>
8. Brownlee W, et al. *Neurology.* 2020 Jun 2;94(22):949-952
9. Louapre C, et al. *JNNP* 2021; <https://doi.org/10.1136/jnnp-2021-326904>
10. Baker, D et al. *Clinical & Experimental Immunology* 202.2 (2020): 149-161.
11. Achiron A, et al. *Ther Adv Neurol Disord.* 2021 Apr 22;14:17562864211012835